DUBLIN--(BUSINESS WIRE)--The "Cardiac Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
The global cardiac biomarkers market was worth US$ 6.9 Billion in 2018. Looking forward, the market value is projected to reach US$ 11.6 Billion by 2024, expanding at a CAGR of around 9% during 2019-2024.
Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers.
In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack.
Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.
Market Summary
Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.
Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.
Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for the majority of the global share.
Key Questions Answered
- How has the global cardiac biomarkers market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global cardiac biomarkers industry?
- What is the breakup of the global cardiac biomarkers market on the basis of type?
- What is the breakup of the global cardiac biomarkers market on the basis of location of testing?
- What is the breakup of the global cardiac biomarkers market on the basis of application?
- What are the various stages in the value chain of the global cardiac biomarkers market?
- What are the key driving factors and challenges in the global cardiac biomarkers market?
- What is the structure of the global cardiac biomarkers market and who are the key players?
- What is the degree of competition in the global cardiac biomarkers market?
Topics Covered
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Cardiac Biomarkers Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Type
5.4 Market Breakup by Location of Testing
5.5 Market Breakup by Application
5.6 Market Breakup by Region
5.7 Market Forecast
6 Market Breakup by Type
6.1 Troponins (T and I)
6.2 Myocardial Muscle Creatine Kinase (CK-MB)
6.3 Myoglobin
6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
6.5 Ischemia Modified Albumin (IMA)
6.6 Others
7 Market Breakup by Location of Testing
7.1 Laboratory Testing
7.2 Point of Care Testing
8 Market Breakup by Application
8.1 Myocardial Infarction
8.2 Congestive Heart Failure
8.3 Acute Coronary Syndrome
8.4 Atherosclerosis
8.5 Others
9 Market Breakup by Region
9.1 North America
9.2 Asia Pacific
9.3 Europe
9.4 Middle East and Africa
9.5 Latin America
10 Global Cardiac Biomarkers Industry: SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Global Cardiac Biomarkers Industry: Value Chain Analysis
12 Global Cardiac Biomarkers Industry: Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Global Cardiac Biomarkers Industry: Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.2 Alere Inc.
14.3.3 Beckman Coulter
14.3.4 Becton, Dickinson and Co.
14.3.5 bioMerieux
14.3.6 Bio-Rad Laboratories
14.3.7 Randox Laboratories
14.3.8 Roche Diagnostics Corporation
14.3.9 Siemens Healthcare
14.3.10 Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/research/mck8zs/the_global_market?w=4
